Upgrade to SI Premium - Free Trial

Regenxbio (RGNX)

10.72 -0.56 (4.96%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/6/26 *Est.)

Latest Headlines

Barclays Downgrades Regenxbio Inc. (RGNX) to Equalweight August 7, 2026 3:32 AM - StreetInsider Barclays Downgrades Regenxbio Inc. (RGNX) to Equalweight August 7, 2026 3:32 AM - StreetInsider Regenxbio (RGNX) Tops Q2 EPS by 18c August 6, 2026 7:39 AM - StreetInsider Form 10-Q REGENXBIO Inc. For: Jun 30 August 6, 2026 7:16 AM - SEC Filing Form 8-K REGENXBIO Inc. For: Aug 06 August 6, 2026 7:10 AM - SEC Filing REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights August 6, 2026 7:05 AM - PR NewsWire Form 4 REGENXBIO Inc. For: Aug 01 Filed by: PAKOLA STEVE August 4, 2026 4:32 PM - SEC Filing Form 4 REGENXBIO Inc. For: Aug 01 Filed by: Christmas Patrick J. August 4, 2026 4:30 PM - SEC Filing REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights August 3, 2026 7:05 AM - PR NewsWire Regenxbio (RGNX) call put ratio 5.2 calls to 1 put with a focus on August 12 calls July 22, 2026 3:58 AM - StreetInsider Form 8-K REGENXBIO Inc. For: Jul 16 July 20, 2026 7:34 AM - SEC Filing Regenxbio shares long-term gene therapy data for eye diseases July 20, 2026 3:19 AM - StreetInsider REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting July 18, 2026 2:55 PM - PR NewsWire Form 424B5 REGENXBIO Inc. July 17, 2026 5:30 PM - SEC Filing Regenxbio prices $100M public offering of stock and warrants July 17, 2026 7:00 AM - StreetInsider REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants July 17, 2026 7:00 AM - PR NewsWire Form FWP REGENXBIO Inc. Filed by: REGENXBIO Inc. July 17, 2026 6:03 AM - SEC Filing After-Hours Stock Movers: NFLX, ISRG, KO, AA, RGNX July 16, 2026 4:44 PM - StreetInsider Form 424B5 REGENXBIO Inc. July 16, 2026 4:32 PM - SEC Filing Regenxbio plans $100M common stock public offering July 16, 2026 4:27 PM - StreetInsider REGENXBIO Announces Proposed Public Offering of Common Stock July 16, 2026 4:26 PM - PR NewsWire Form 4 REGENXBIO Inc. For: Dec 31 Filed by: Simpson Curran July 6, 2026 4:52 PM - SEC Filing Form 4 REGENXBIO Inc. For: Jul 02 Filed by: PAKOLA STEVE July 6, 2026 4:51 PM - SEC Filing Form SC TO-I/A REGENXBIO Inc. Filed by: REGENXBIO Inc. July 6, 2026 8:01 AM - SEC Filing Form 4 REGENXBIO Inc. For: Jun 29 Filed by: PAKOLA STEVE July 1, 2026 8:09 PM - SEC Filing Form 144 REGENXBIO Inc. Filed by: PAKOLA STEVE July 1, 2026 4:32 PM - SEC Filing Form SC TO-I/A REGENXBIO Inc. Filed by: REGENXBIO Inc. July 1, 2026 9:11 AM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) July 1, 2026 7:00 AM - StreetInsider Form 8-K REGENXBIO Inc. For: Jun 23 June 29, 2026 7:15 AM - SEC Filing Regenxbio doses first patient in diabetic retinopathy gene therapy trial June 29, 2026 7:05 AM - StreetInsider REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone June 29, 2026 7:05 AM - PR NewsWire H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) June 25, 2026 6:49 AM - StreetInsider RegenxBio completes dosing in RGX-202 confirmatory Duchenne study June 24, 2026 7:05 AM - StreetInsider REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 June 24, 2026 7:05 AM - PR NewsWire H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) June 23, 2026 6:51 AM - StreetInsider Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink June 22, 2026 10:21 AM - StreetInsider Regenxbio Inc. (RGNX) PT Raised to $32 at Baird June 22, 2026 9:50 AM - StreetInsider FDA aligns with Regenxbio on path to refile MPS II gene therapy BLA June 22, 2026 7:31 AM - StreetInsider REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II June 22, 2026 7:30 AM - PR NewsWire Regenxbio shares jump after FDA agrees to reverse drug rejection June 22, 2026 6:43 AM - StreetInsider Regenxbio Inc. (RGNX) PT Lowered to $26 at H.C. Wainwright June 8, 2026 6:54 AM - StreetInsider Form SCHEDULE 13G/A REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO June 4, 2026 1:10 PM - SEC Filing Form SC TO-I REGENXBIO Inc. Filed by: REGENXBIO Inc. June 3, 2026 8:12 AM - SEC Filing Form 8-K REGENXBIO Inc. For: May 29 June 3, 2026 7:30 AM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Tasse Daniel June 2, 2026 5:21 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: STUMP DAVID C June 2, 2026 5:21 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Zachary Jennifer June 2, 2026 5:21 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Mills Kenneth T. June 2, 2026 5:17 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: MIGAUSKY GEORGE V June 2, 2026 5:17 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: KARABELAS ARGERIS N June 2, 2026 5:16 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Glucksmann Alexandra June 2, 2026 5:16 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Fox Allan M. June 2, 2026 5:16 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Bennett Jean June 2, 2026 5:15 PM - SEC Filing Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX) May 27, 2026 9:13 AM - StreetInsider REGENXBIO to Participate in Upcoming Investor Conferences May 18, 2026 4:05 PM - PR NewsWire Regenxbio Inc. (RGNX) PT Lowered to $16 at Morgan Stanley May 15, 2026 8:44 AM - StreetInsider Regenxbio Inc. (RGNX) PT Lowered to $10 at Goldman Sachs May 15, 2026 4:56 AM - StreetInsider Regenxbio Inc. (RGNX) PT Lowered to $12 at Barclays May 15, 2026 4:43 AM - StreetInsider Form 10-Q REGENXBIO Inc. For: Mar 31 May 14, 2026 7:31 AM - SEC Filing Form 8-K REGENXBIO Inc. For: May 14 May 14, 2026 7:15 AM - SEC Filing Regenxbio (RGNX) Misses Q1 EPS by 38c, Misses on Revenue May 14, 2026 7:12 AM - StreetInsider REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights May 14, 2026 7:10 AM - PR NewsWire REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 May 14, 2026 7:00 AM - PR NewsWire Form 4 REGENXBIO Inc. For: May 11 Filed by: PAKOLA STEVE May 13, 2026 5:19 PM - SEC Filing Form SCHEDULE 13G REGENXBIO Inc. Filed by: STATE STREET CORP May 12, 2026 11:54 AM - SEC Filing Form 144 REGENXBIO Inc. Filed by: PAKOLA STEVE May 11, 2026 4:36 PM - SEC Filing Full Article List